Signaling pathways such as PI3K/Akt, Stat3, NF-κB and HIF-1 play key roles in expression of PD-L1 [70], butyrate has been shown to inhibit these signaling pathways, which may result in decreased PD-L1 expression and increased anti-cancer immune responses. Here, AKT1 is linked to cancer.